The #1 Dermatologist-Recommended Facial Skincare Brand Introduces Six New Product Launches, Specifically Formulated for Dry, Sensitive Skin

• First approval for a class III medical device for improved skin appearance in China
• First introduction of the new product category “Skinboosters” in China

Spotlighting the long-term safety and efficacy profile of Dysport for aesthetic use and the natural results yielding high patient satisfaction

Lausanne, Switzerland – March 8, 2019 –Galderma, Nestlé Skin Health’s medical solutions business, presented the final results from a Phase 2b dose-ranging study of nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis (AD), at the late-breaking session of the 2019 American Academy of Dermatology annual meeting (March 1-5).

• Updated administration protocol means Sculptra^® offers the fastest reconstitution of any injectable poly-L-lactic acid (PLLA) available in Europe
• Updated protocol allows for faster and more convenient administration of Sculptra^® with the optional addition of lidocaine to increase patient comfort
• Update i